SKLB325
SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (KD) value of 0.755 μM, and the IC50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis[1]. SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) [2].
Product Specifications
CAS Number
66680-03-3
UNSPSC
12352005
Target
Apoptosis; Histone Demethylase
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sklb325.html
Purity
99.23
Solubility
DMSO : 20.83 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
OC1=NC(N/N=C/C2=CC=CC=C2O)=NC(C)=C1
Molecular Formula
C12H12N4O2
Molecular Weight
244.25
References & Citations
[1]Heng Zheng, et al. Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer. Signal Transduct Target Ther.2019 Jul 26;4:24.|[2]Chuanjie Zhang, et al. Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma. Clin Transl Med. 2021 Feb;11 (2) :e328.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880003-100 1x 100 µL
CD45RO (UCHL-1), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940391-100 1x 100 µL
CD81 / TAPA-1 (1.3.3.22), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC942853-500 1x 500 µL
CD54 / ICAM-1 (15.2), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040149-100 1x 100 µL
CD106 / VCAM1 (1.4C3), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details